Ayala Pharmaceuticals is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Ayalaâ??s approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL02, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer, T-cell Acute Lymphoblastic Leukemia, Desmoid Tumors and Multiple Myeloma (in collaboration with Novartis).
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
21
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Ayala Pharmaceuticals Inc market cap is $7.46M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Ayala Pharmaceuticals Inc 52 week high is $7.13 as of November 16, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Ayala Pharmaceuticals Inc 52 week low is $0.3568 as of November 16, 2026.
Ayala Pharmaceuticals Inc stock price today is $0.4758.
Ayala Pharmaceuticals Inc stock price yesterday was $0.4758.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Ayala Pharmaceuticals Inc's P/E ratio is -0.2.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Ayala Pharmaceuticals Inc P/B ratio is 0.8828.
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company's operations. Ayala Pharmaceuticals Inc's EBITDA is N/A.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Ayala Pharmaceuticals Inc 50-day moving average is $0.5277.